INCANNEX HEALTHCARE LIMITED (ASX:IHL) - General discussion, 69179102, page-16489 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Australia's largest stock trading and investment forum Australia's #1 stock forum

IHL

Click for more information

0.00%

4.1¢ incannex healthcare limited

First 16489 Last

Share
Profile

Follow
2much_red

182 Posts.

85

05/08/23

18:27

Post #: 69179102
Share

Originally posted by kingkev: ↑

Possibility of shorters taking the reigns is also not out of the question

see below

Key risks
Biotech, however, is not an easy space for retail investors to navigate. Although mid- to large-cap biotech companies tend to be less volatile, investors should be mindful that in the small-cap and micro-cap biotech space there will be volatility. Most companies at the smaller end of the biotech sector will not as yet have earnings, revenue or even a product approved and in the market.
Although clinical or regulatory success offers significant returns quickly, failure of a clinical trial or regulatory setback is likely to lead to significant losses in a relatively short time. Also, for early-stage companies running clinical trials, results can sometimes be hard to interpret, and the underlying science is typically not easy for a layman to understand.
Valuation of clinical-stage companies, where probability of success is used to risk-adjust future revenue dependent on the clinical stage of development, adds another layer of complexity for the typical investor.

sounds a bit like where we sit atm and this is somewhat attractive to shorters

Just some out-there thinking

Expand

TThe only thing being didcounted is the share price... i effing hate shorters especially in this market segment.. but hey the ASX allows it, so what can you do....

Nasdaq looks like a huge mistake, and i can see my money going bye bye... i hate that im emotionally caught in this stock.. i hate even more that i didnt sell at 60-70cents.

I'm still green ( barely) but fearful of what's coming

Originally posted by kingkev: ↑

Possibility of shorters taking the reigns is also not out of the question

see below

Key risks
Biotech, however, is not an easy space for retail investors to navigate. Although mid- to large-cap biotech companies tend to be less volatile, investors should be mindful that in the small-cap and micro-cap biotech space there will be volatility. Most companies at the smaller end of the biotech sector will not as yet have earnings, revenue or even a product approved and in the market.
Although clinical or regulatory success offers significant returns quickly, failure of a clinical trial or regulatory setback is likely to lead to significant losses in a relatively short time. Also, for early-stage companies running clinical trials, results can sometimes be hard to interpret, and the underlying science is typically not easy for a layman to understand.
Valuation of clinical-stage companies, where probability of success is used to risk-adjust future revenue dependent on the clinical stage of development, adds another layer of complexity for the typical investor.

sounds a bit like where we sit atm and this is somewhat attractive to shorters

Just some out-there thinking

Expand

Originally posted by kingkev: ↑

Possibility of shorters taking the reigns is also not out of the question

see below

Key risks
Biotech, however, is not an easy space for retail investors to navigate. Although mid- to large-cap biotech companies tend to be less volatile, investors should be mindful that in the small-cap and micro-cap biotech space there will be volatility. Most companies at the smaller end of the biotech sector will not as yet have earnings, revenue or even a product approved and in the market.
Although clinical or regulatory success offers significant returns quickly, failure of a clinical trial or regulatory setback is likely to lead to significant losses in a relatively short time. Also, for early-stage companies running clinical trials, results can sometimes be hard to interpret, and the underlying science is typically not easy for a layman to understand.
Valuation of clinical-stage companies, where probability of success is used to risk-adjust future revenue dependent on the clinical stage of development, adds another layer of complexity for the typical investor.

sounds a bit like where we sit atm and this is somewhat attractive to shorters

Just some out-there thinking

Expand

IHL Price at posting: 9.0¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Microcap Wrap: 5 explorers with news out today

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

RCE

Recce's R327 found effective against E.coli during clinical trial

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

There are more pages in this discussion • 3,408 more messages in this thread...

First 16489 Last

Add IHL (ASX) to my watchlist

SPONSORED BY